Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry-Reference-Cited by-同舟云学术

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

Published:2022-12-09 Issue:2 Volume:13 Page:487-504
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Armstrong April W.,Fitzgerald Timothy^ORCID,McLean Robert R.,Teeple Amanda,Uy Jonathan P.,Olurinde Mobolaji,Rowland Katelyn,Guo Lin,Shan Ying,Callis Duffin Kristina

Funder

Janssen Biotech

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-022-00865-0.pdf

Reference59 articles.

1. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Molec Sci. 2019;20(6):1475.

2. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

3. Boehncke WH, Schon MP. Psoriasis Lancet. 2015;386(9997):983–94.

4. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–6.

5. Papp KA, Gniadecki R, Beecker J, Dutz J, Gooderham MJ, Hong CH, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther (Heidelb). 2021;11(3):1053–64.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study;Experimental Dermatology;2023-10-21

2. Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries;Journal of Clinical Medicine;2023-09-01

3. The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry;Advances in Therapy;2023-03-17

4. Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry;Dermatology and Therapy;2022-12-31